[go: up one dir, main page]

PL3773735T3 - Koniugat leku cytotoksycznego i postać proleku koniugatu - Google Patents

Koniugat leku cytotoksycznego i postać proleku koniugatu

Info

Publication number
PL3773735T3
PL3773735T3 PL19713507.2T PL19713507T PL3773735T3 PL 3773735 T3 PL3773735 T3 PL 3773735T3 PL 19713507 T PL19713507 T PL 19713507T PL 3773735 T3 PL3773735 T3 PL 3773735T3
Authority
PL
Poland
Prior art keywords
conjugate
cytotoxic drug
prodrug form
drug conjugate
prodrug
Prior art date
Application number
PL19713507.2T
Other languages
English (en)
Inventor
Oleksandr Koniev
Sergii KOLODYCH
Jean-Yves Bonnefoy
Original Assignee
Syndivia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syndivia filed Critical Syndivia
Publication of PL3773735T3 publication Critical patent/PL3773735T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
PL19713507.2T 2018-04-03 2019-04-02 Koniugat leku cytotoksycznego i postać proleku koniugatu PL3773735T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18305390 2018-04-03
PCT/EP2019/058226 WO2019192979A1 (en) 2018-04-03 2019-04-02 Conjugate of cytotoxic drug and prodrug form of said conjugate

Publications (1)

Publication Number Publication Date
PL3773735T3 true PL3773735T3 (pl) 2025-01-20

Family

ID=61965888

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19713507.2T PL3773735T3 (pl) 2018-04-03 2019-04-02 Koniugat leku cytotoksycznego i postać proleku koniugatu

Country Status (22)

Country Link
US (1) US20210023113A1 (pl)
EP (1) EP3773735B1 (pl)
JP (1) JP7397058B2 (pl)
KR (2) KR20250117704A (pl)
CN (2) CN120078904A (pl)
AU (1) AU2019248589B2 (pl)
CA (1) CA3095146A1 (pl)
DK (1) DK3773735T3 (pl)
EA (1) EA202092361A1 (pl)
ES (1) ES2989309T3 (pl)
FI (1) FI3773735T3 (pl)
HR (1) HRP20241363T1 (pl)
HU (1) HUE068574T2 (pl)
IL (1) IL277693B2 (pl)
LT (1) LT3773735T (pl)
MX (1) MX2020010201A (pl)
PL (1) PL3773735T3 (pl)
PT (1) PT3773735T (pl)
RS (1) RS66033B1 (pl)
SI (1) SI3773735T1 (pl)
SM (1) SMT202400404T1 (pl)
WO (1) WO2019192979A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114437151B (zh) * 2020-11-03 2023-12-01 华东师范大学 白蛋白结合型喜树碱衍生物前药及其制备方法与应用
FR3126982B1 (fr) * 2021-09-14 2023-09-15 Centre Nat Rech Scient Vecteurs ciblant la beta-d-n-acetylglucosaminidase
CN114085256B (zh) * 2021-11-23 2024-03-19 江南大学 一种β-半乳糖苷酶响应的糖类衍生物及其应用
CN114957356B (zh) * 2022-06-17 2024-10-01 江南大学 一种β-葡萄糖醛酸酶响应的糖类衍生物及其制备方法与应用
CN120936385A (zh) 2023-03-13 2025-11-11 海德堡医药研究有限责任公司 用于在癌症治疗中使用的皮下施用的抗体-药物缀合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2960153B1 (fr) * 2010-05-20 2012-08-17 Centre Nat Rech Scient Nouveaux bras autoreactifs et prodrogues les comprenant
EP3066120B1 (en) 2013-11-04 2018-10-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Synthetic single domain antibody
FR3017298B1 (fr) * 2014-02-07 2016-03-04 Centre Nat Rech Scient Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires

Also Published As

Publication number Publication date
JP2021520409A (ja) 2021-08-19
ES2989309T3 (es) 2024-11-26
SMT202400404T1 (it) 2024-11-15
SI3773735T1 (sl) 2025-03-31
MX2020010201A (es) 2020-12-10
HRP20241363T1 (hr) 2024-12-20
DK3773735T3 (da) 2024-10-21
FI3773735T3 (fi) 2024-10-14
HUE068574T2 (hu) 2025-01-28
CN112004556A (zh) 2020-11-27
IL277693B1 (en) 2023-10-01
IL277693B2 (en) 2024-02-01
WO2019192979A1 (en) 2019-10-10
AU2019248589A1 (en) 2020-10-22
CN120078904A (zh) 2025-06-03
JP7397058B2 (ja) 2023-12-12
EP3773735A1 (en) 2021-02-17
EA202092361A1 (ru) 2021-02-02
US20210023113A1 (en) 2021-01-28
KR20210018208A (ko) 2021-02-17
EP3773735B1 (en) 2024-07-10
KR102840665B1 (ko) 2025-07-30
KR20250117704A (ko) 2025-08-05
CA3095146A1 (en) 2019-10-10
PT3773735T (pt) 2024-10-10
RS66033B1 (sr) 2024-11-29
IL277693A (en) 2020-11-30
LT3773735T (lt) 2024-10-25
AU2019248589B2 (en) 2025-10-23

Similar Documents

Publication Publication Date Title
IL283134A (en) Alcohol-resistant drug formulations
EP3904351A4 (en) FAK INHIBITOR AND COMBINATION OF ACTIVE SUBSTANCES THEREOF
EP3572428A4 (en) ANTI-BODY ANTI-GPR20 AND ANTI-BODY-DRUG CONJUGATE ANTI-GPR20
PL3773735T3 (pl) Koniugat leku cytotoksycznego i postać proleku koniugatu
EP3548000A4 (en) PHARMACEUTICAL COMPOSITIONS OF ATROPINE
EP3463228A4 (en) INTRAOCULAR DELIVERY
IL264065A (en) Oral gastroretentive formulations and uses thes thereof
EP3604311A4 (en) PYRROLOBENZODIAZEPINE DIMERIC PRECURSOR AND ASSOCIATED LIGAND-BOND CONJUGATE COMPOUND
DK3870234T3 (da) Antistoflægemiddelkonjugater omfattende ecteinascidinderivater
EP3638248A4 (en) CONJUGATES OF PHARMACEUTICAL INGREDIENTS
EP3795151A4 (en) ANTITUMOR NANODRUG
MA46867A (fr) Formulations pharmaceutiques
MA55015A (fr) Formulations pharmaceutiques
EP3643353A4 (en) ROBOTS FOR DRUG DISPENSING
EP3908251C0 (en) COMPOSITIONS FOR ADMINISTERING PHARMACEUTICAL PRODUCTS AND USES THEREOF
HUE053616T2 (hu) Anti-SEZ6 antitest-hatóanyag konjugátumok és alkalmazási eljárások
EP3595670A4 (en) MEDICINAL-POLYMER CONJUGATE
EP3773654C0 (en) POLYPHARMACEUTICAL DRUG COMPOSITIONS AND ASSOCIATED METHODS
MA49837A (fr) Compositions pharmaceutiques
IL282157A (en) Compounds and therapeutic uses thereof
IL282343A (en) Aqueous pharmaceutical formulations
EP3733243A4 (en) METHOD OF DRUG ADMINISTRATION
LT3601277T (lt) Farmacinė vaisto forma
EP3590513A4 (en) DRUG
EP4069214C0 (en) POLYPHOSPHAZENE-BASED DRUG CARRIERS